Development for new cancer vaccine using various kinds of epitope peptides

利用多种表位肽开发新型癌症疫苗

• 批准号: 14571128
• 负责人: TSUNODA Takuya
• 金额: $ 2.05万
• 依托单位: The University of Tokyo
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14571128/
• 关键词: Epitope peptide; HER2; neu; p53; CTL; Cancer vaccine; がんワクチン療法

Recently, cancer vaccine using epitope peptides was performed all over the world. Epitope peptides induced the strong cytotoxic T lymphocytes (CTL) in cancer patients, therefore clinical trials of cancer vaccine were performed. However, the outcome of clinical trial has not so excellent. One of the reasons was due to the only one target against the cancer. To promote the clinical efficacy, it is important to find the more epitope peptides. In this study, we determined the epitope peptides from HER2/neu and p53 which were significant molecules for cancer. We determined epitope peptides restricted to HLA-A*2402 which was the most common in Japanese. These findings may suggest that mixture of the epitope peptides improve the clinical efficacy of cancer vaccine.

近年来，利用表位肽的癌症疫苗在世界各地进行。表位肽在肿瘤患者体内可诱导出较强的细胞毒性T淋巴细胞（CTL），因此肿瘤疫苗开始了临床试验。然而，临床试验的结果并不理想。其中一个原因是由于针对癌症的唯一目标。为了提高临床疗效，寻找更多的表位肽具有重要意义。在这项研究中，我们确定了来自HER 2/neu和p53的表位肽，它们是癌症的重要分子。我们确定了限制于HLA-A*2402的表位肽，这是日本人中最常见的。这些结果可能表明，表位肽的混合物提高了癌症疫苗的临床疗效。

项目成果

Matsuda K, Tsunoda T., et al.: "Enhancement of Cytotoxic T Lymphocyte Responses in Patients with Gastrointestinal Malignancies following Vaccination with CEA peptide pulsed Dendritic cells."Cancer Immunology Immunotherpy. Jan 20(Epub ahead of print). (200

Matsuda K、Tsunoda T. 等人：“胃肠道恶性肿瘤患者在接种 CEA 肽脉冲树突状细胞后细胞毒性 T 淋巴细胞反应的增强”。癌症免疫学免疫疗法。

Matsuda K, Tsunoda T., et al.: "Enhancement of Cytotoxic T Lymphocyte Responese in Patients with Gastrointestinal Malignancies following Vaccination with CEA peptide pulsed Dendritic cells"Cancer Immunology Immunotherpy. Jan20(Epub ahead of print). (2004)

Matsuda K、Tsunoda T. 等人：“用 CEA 肽脉冲树突状细胞接种疫苗后胃肠道恶性肿瘤患者细胞毒性 T 淋巴细胞反应的增强”癌症免疫学免疫疗法。

Saori Nakahara, Takuya Tsunoda, et al.: "Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide."Cancer Research. 63. 4112-4118 (2003)

Saori Nakahara、Takuy​​a Tsunoda 等人：“用细菌产品 OK-432 刺激树突状细胞，可有效诱导对肿瘤排斥肽具有特异性的细胞毒性 T 淋巴细胞。”癌症研究。

Shono Y, Tanimura H, Iwahashi M, Tsunoda T, et al.: "Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers."Br J Cancer. 88. 530-536 (2003)

Shono Y、Tanimura H、Iwahashi M、Tsunoda T 等人：“胰腺癌和结直肠癌患者针对 Ki-ras 肽的特异性 T 细胞免疫。”Br J Cancer。

Saori Nakahara, Tsunoda T., et al.: "Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide."Cancer Research. 63. 4112-4118 (2003)

Saori Nakahara、Tsunoda T. 等人：“用细菌产品 OK-432 刺激树突状细胞，可有效诱导对肿瘤排斥肽具有特异性的细胞毒性 T 淋巴细胞。”癌症研究。